Log in

NASDAQ:BPTHBio-Path Stock Price, Forecast & News

-0.03 (-0.60 %)
(As of 07/14/2020 04:00 PM ET)
Today's Range
Now: $4.94
50-Day Range
MA: $5.23
52-Week Range
Now: $4.94
Volume64,200 shs
Average Volume100,335 shs
Market Capitalization$18.24 million
P/E RatioN/A
Dividend YieldN/A
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Read More
Bio-Path logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BPTH



Sales & Book Value

Annual Sales$40,000.00
Book Value$7.31 per share


Net Income$-8,600,000.00


Market Cap$18.24 million
Next Earnings Date8/20/2020 (Estimated)
OptionableNot Optionable

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

How has Bio-Path's stock been impacted by COVID-19 (Coronavirus)?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BPTH shares have increased by 4.0% and is now trading at $4.94. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bio-Path.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Bio-Path.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) announced its quarterly earnings data on Friday, May, 15th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.23. View Bio-Path's earnings history.

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

1 brokers have issued 1 year target prices for Bio-Path's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Bio-Path's share price to reach $18.00 in the next year. This suggests a possible upside of 264.4% from the stock's current price. View analysts' price targets for Bio-Path.

What are Wall Street analysts saying about Bio-Path stock?

Here are some recent quotes from research analysts about Bio-Path stock:
  • 1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (6/16/2020)
  • 2. HC Wainwright analysts commented, "We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate." (8/16/2019)

Has Bio-Path been receiving favorable news coverage?

Headlines about BPTH stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bio-Path earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the near future. View the latest news about Bio-Path.

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include Advanced Micro Devices (AMD), Amarin (AMRN), NVIDIA (NVDA), Micron Technology (MU), Anavex Life Sciences (AVXL), Canopy Growth (CGC), TrovaGene (TROV), Agile Therapeutics (AGRX), Energy Transfer LP Unit (ET) and OpGen (OPGN).

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $4.94.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $18.24 million and generates $40,000.00 in revenue each year. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Bio-Path employs 8 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is www.biopathholdings.com.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.